Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AC Immune SA (ACIU – Research Report), Alnylam Pharma (ALNY – Research Report) and Insmed (INSM – Research Report) with bullish sentiments.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AC Immune SA (ACIU)
In a report released yesterday, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AC Immune SA, with a price target of $12.00. The company’s shares closed last Wednesday at $2.85.
According to TipRanks.com, Fein is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AC Immune SA with a $10.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Alnylam Pharma (ALNY)
H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Alnylam Pharma yesterday and set a price target of $570.00. The company’s shares closed last Wednesday at $473.29.
According to TipRanks.com, Trucchio is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $497.68 average price target, a 6.7% upside from current levels. In a report issued on December 1, Piper Sandler also reiterated a Buy rating on the stock with a $489.00 price target.
Insmed (INSM)
Insmed received a Buy rating and a $263.00 price target from Rothschild & Co Redburn analyst Qize Ding today. The company’s shares closed last Wednesday at $206.78.
According to TipRanks.com, Ding is ranked #6567 out of 10113 analysts.
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $211.44, representing a 2.3% upside. In a report issued on November 19, Jefferies also maintained a Buy rating on the stock with a $230.00 price target.
